Omada Health, Inc. (NASDAQ:OMDA) Given Average Recommendation of “Moderate Buy” by Analysts

Omada Health, Inc. (NASDAQ:OMDA) has earned an average rating of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $22.90.

A number of brokerages have weighed in on OMDA. Barclays lowered their price objective on Omada Health from $22.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Wells Fargo & Company began coverage on Omada Health in a research note on Thursday, January 8th. They set an “equal weight” rating and a $17.00 target price for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Omada Health in a research report on Thursday, January 22nd. BMO Capital Markets dropped their price target on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday. Finally, Morgan Stanley cut their target price on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday.

Insider Activity

In other Omada Health news, President Wei-Li Shao sold 5,618 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $16.13, for a total transaction of $90,618.34. Following the sale, the president owned 69,079 shares in the company, valued at $1,114,244.27. This represents a 7.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Sean P. Duffy sold 40,796 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $15.95, for a total value of $650,696.20. Following the sale, the chief executive officer owned 126,644 shares in the company, valued at $2,019,971.80. The trade was a 24.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 276,893 shares of company stock valued at $4,336,787.

Hedge Funds Weigh In On Omada Health

Large investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new position in shares of Omada Health in the 2nd quarter worth about $640,000. Geode Capital Management LLC acquired a new position in shares of Omada Health during the second quarter valued at $637,000. Franklin Resources Inc. bought a new position in shares of Omada Health during the second quarter worth about $2,695,000. Eisler Capital Management Ltd. bought a new stake in Omada Health in the 2nd quarter valued at about $545,000. Finally, XTX Topco Ltd bought a new stake in Omada Health in the 2nd quarter valued at about $414,000.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

Omada Health Price Performance

Shares of OMDA stock opened at $14.05 on Friday. The company’s fifty day moving average price is $14.03 and its two-hundred day moving average price is $18.67. The firm has a market capitalization of $813.61 million and a P/E ratio of -56.20. Omada Health has a 12 month low of $10.28 and a 12 month high of $28.40.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, March 5th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.12. The business had revenue of $75.85 million for the quarter.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.